Dr. Hossein Borghaei is the Chief of Thoracic Medicinal Oncology at Fox Chase Cancer Center. Dr. Borghaei earned his degree at Philadelphia College of Osteopathic Medicine and completed a residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer.
In addition to his clinical practice and participation in immunotherapy-based clinical trials, Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic.
Dr. Borghaei is the co-chair of the thoracic committee at Eastern Cooperative Oncology Group (ECOG) and the Chair of the LungMap trial (S1800/S1900). He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. He also is the recipient of the Robert Krigel Memorial Award for Teaching Excellence from Fox Chase Cancer Center. Dr. Borghaei is a long-standing member of ASCO, AACR, IASLC, SITC and ECOG thoracic committee.
Professor Thomas Powles is the Chair of Barts Cancer Centre, London. He leads the Experimental Cancer Medicine Centre and Biomedical Research Cancer Grants at Barts/QMUL. He has led 23 randomised cancer trials including studies which resulted in multiple EMA and FDA approvals. He has led clinical and high impact translational science projects. He has an H-index of 100 and has given plenary presentations at the major cancer meeting. Barts. He co-leads the Uromigos podcast and European Guidelines for GU cancer. He is editor in chief of the Annals of Oncology Journal. In 2023 he was selected a Nature’s 10 global scientist and in 2024 TIME magazines 100 healthcare list.
Dr. Lillian Siu is a senior medical oncologist at Princess Margaret Cancer Centre, and is a Professor of Medicine at the University of Toronto. She is the Director of the Phase I Trials Program, co-leads the Tumor Immunotherapy Program and holds the BMO Chair in Precision Genomics. Dr. Siu’s major research focus is in the area of new anticancer drug development, with respect to phase I trials and head and neck malignancies. Her translational research focus is in the area of liquid biopsies, predictive biomarkers and precision medicine. Internationally, Dr. Siu was the recipient of the US National Cancer Institute’s Michaele C. Christian Award in 2010, European Society of Medical Oncology’s Targeted Anticancer Therapies (TAT) Honorary Award in 2020, Canadian Cancer Trials Group’s Maria Ricci Memorial Lectureship in 2023, and ASCO’s highest honor - David A. Karnofsky Memorial Award in 2024. Dr. Siu received the 2024 Life Time Achievement Award from the Chinese American Hematologist and Oncologist Network (CAHON). For her mentorship of early career investigators, Dr. Siu received the International Women Who Conquer Cancer Mentorship Award from ASCO in 2020.
Dr. Sara Tolaney, M.D., M.P.H., is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and is internationally recognized for her research and educational leadership in breast cancer. Dr. Tolaney also serves as Associate Director of the Susan F. Smith Center for Women's Cancers and is an Associate Professor of Medicine at Harvard Medical School. Dr. Tolaney’s research focuses on the development of novel therapies in breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low-risk regimen is beneficial in women with early-stage node-negative HER2-positive cancers, and this work has been incorporated into national and international guidelines. Dr. Tolaney has developed several follow-up studies looking at novel approaches to early-stageHER2-positive disease and has also played a significant role in the development of CDK 4/6 inhibitors, antibody-drug conjugates, and immunotherapy in breast cancer.
